When considering prescription medications for weight loss, two common options are Zepbound (tirzepatide) and Saxenda (liraglutide). While both support weight management, they differ in formulation, dosing, side effects, and long-term effectiveness. Let’s break down their similarities and differences so you can make an informed choice.
Zepbound vs Saxenda Comparison Table
| Feature | Zepbound (Tirzepatide) | Saxenda (Liraglutide) |
|---|---|---|
| FDA Approval | Approved in 2023 for chronic weight management | Approved in 2014 for chronic weight management |
| Mechanism of Action | Dual GIP & GLP-1 receptor agonist | GLP-1 receptor agonist |
| Administration | Weekly injection | Daily injection |
| Dosage Options | 2.5 mg to 15 mg (weekly) | 0.6 mg to 3 mg (daily) |
| Average Weight Loss | Up to 22.5% of body weight in trials | Around 5–10% of body weight in trials |
| Common Side Effects | Nausea, vomiting, diarrhea, constipation, fatigue | Nausea, vomiting, diarrhea, constipation, low appetite |
| Cost | Often higher due to newer drug status | Typically lower than Zepbound |
| Insurance Coverage | Limited, varies by plan | Broader coverage due to longer availability |
| Best For | Patients seeking maximum weight loss results and less frequent dosing | Patients preferring a longer-established option with more insurance support |
Key Takeaways
-
Zepbound is a newer, highly effective option with weekly dosing and greater average weight loss results. It is manufactured by Eli Lilly
-
Saxenda is more established, widely covered by insurance, but requires daily injections and may result in less dramatic weight reduction. It is manufactured by Novo Nordisk
-
Choice often depends on your treatment goals, insurance coverage, and tolerance to injections.